PPAR

GW409544 is a highly potent activator of both PPARα and PPARγ, exhibiting EC50 values of 2.3 nM and 0.28 nM, respectively. This compound plays a significant role in the regulation of lipid metabolism and glucose homeostasis. GW409544 is instrumental for research investigating mechanisms underlying metabolic disorders and cardiovascular diseases, providing insights into potential therapeutic approaches.

CLX-0921 is an orally active PPARγ agonist, with an IC50 of 1.54 μM. It exhibits potent antihyperglycemic activity, making it a valuable tool for research in type 2 diabetes. This compound aids in the investigation of metabolic regulation and related therapeutic strategies in glucose homeostasis.

N-Octadecyl-N'-propyl-sulfamide is a selective agonist of peroxisome proliferator-activated receptor alpha (PPARα), demonstrating an EC50 of 100 nM. As an analog of oleoylethanolamide (OEA), it activates PPARα, playing a critical role in lipid and glucose metabolism. In animal models, the compound significantly reduces food intake and body weight gain, with a notable effect observed in both free-feeding Wistar rats and obese Zucker (fa/fa) rats, particularly at doses of 1 mg/kg. Additionally, a dose of 10 mg/kg administered intraperitoneally effectively inhibits appetite and lowers plasma triglyceride levels.

NS-220 is a potent and selective agonist of PPARα, exhibiting an EC50 value of 1.9 × 10^-8 M for PPARα, while demonstrating significantly lower affinity for PPARγ and PPARδ (9.6 × 10^-6 M and >10^-4 M, respectively). This compound is instrumental in research focused on hyperlipidemia and metabolic disorders associated with type-2 diabetes, aiding in the exploration of therapeutic strategies targeting lipid metabolism and glucose homeostasis.

PPARα/γ/δ Agonist 1 is a potent agonist of the peroxisome proliferator-activated receptors α, γ, and δ, exhibiting an IC50 of 70 nM for PPARγ. This compound is primarily utilized in research focused on type 2 diabetes, facilitating studies on metabolic regulation and potential therapeutic strategies. Its ability to activate multiple PPAR subtypes makes it a valuable tool for investigating lipid metabolism and glucose homeostasis.

BM152054 is a potent PPARgamma activator that enhances insulin action and promotes glucose utilization in peripheral tissues. This compound is crucial for research focused on metabolic disorders and diabetes, offering insights into the regulatory mechanisms of lipid and glucose metabolism. Its ability to modulate PPARgamma activity makes it a valuable tool for investigating therapeutic strategies targeting insulin sensitivity and metabolic health.

PPARα-MO-1 is a potent modulator of peroxisome proliferator-activated receptor alpha (PPARα), contributing to lipid metabolism and glucose homeostasis. This compound has potential applications in the study of metabolic disorders, including obesity and type 2 diabetes, by regulating gene expression involved in fatty acid oxidation and inflammation. It serves as an important tool for researchers investigating the role of PPARα in metabolic pathways and therapeutic strategies.

Perfluoro(2-methyl-3-oxahexanoic) acid is a potent agonist of peroxisome proliferator-activated receptor α (PPARα), exhibiting an EC50 of 2.1 μM for human PPARα. This compound plays a critical role in inducing peroxisome proliferation and elevating proinflammatory mediators, which can lead to impaired intestinal barrier function and disrupted cecal flora balance. Its applications span research into developmental toxicity, hepatotoxicity, and intestinal toxicity, providing valuable insights into these biological processes.

AI 3-25755 is a potent agonist of peroxisome proliferator-activated receptor gamma (PPARγ). This compound demonstrates significant biological activity in modulating PPARγ pathways, making it valuable for research into metabolic disorders. AI 3-25755 is particularly relevant for studies investigating mechanisms underlying opioid abuse and smoking cessation, providing insights into addiction and withdrawal processes.